|
Apalutamide (APA) plus intermittent versus continuous androgen-deprivation therapy (ADT) in participants (pts) with metastatic castration-sensitive prostate cancer (mCSPC): LIBERTAS phase 3 study design. |
|
|
Honoraria - Aculeus Therapeutics; Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi Sankyo; Ipsen; Janssen; Merck Serono; Merck Sharp & Dohme; Novartis; Noxopharm; Pfizer; Sanofi; Telix Pharmaceuticals; Tolmar |
Consulting or Advisory Role - Aculeus Therapeutics; Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi Sankyo; Ipsen; Janssen; Merck Serono; Merck Sharp & Dohme; Novartis; Noxopharm; Pfizer; Sanofi; Telix Pharmaceuticals; Tolmar |
Speakers' Bureau - Amgen; Astellas Pharma; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Merck Serono; Novartis |
Research Funding - Aptevo Therapeutics (Inst); Astellas Pharma; Astellas Pharma (Inst); AstraZeneca; AstraZeneca (Inst); Bionomics (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Hinova Pharmaceuticals (Inst); Ipsen (Inst); Janssen (Inst); Lilly (Inst); MedImmune (Inst); Merck Serono; Merck Serono (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst); Synthorx (Inst) |
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; Janssen; Merck Serono; Pfizer; Sanofi; Tolmar |
|
|
|
Consulting or Advisory Role - Janssen |
Speakers' Bureau - Janssen |
Research Funding - Janssen Oncology |
Patents, Royalties, Other Intellectual Property - patent pending BIO-MECHANICAL PROSTHESIS OF URINARY BLADDER |
Expert Testimony - Janssen |
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Bayer; Janssen Oncology |
|
|
No Relationships to Disclose |
|
|
Honoraria - Advanced Accelerator Applications; Astellas Pharma; Astellas Scientific and Medical Affairs Inc; AstraZeneca; Bayer; Clovis Oncology; Exelixis; Genentech; Janssen; Janssen; Janssen Oncology; Merck; Myovant Sciences; Pfizer; Sanofi; Telix Pharmaceuticals |
Consulting or Advisory Role - Advanced Accelerator Applications; Astellas Pharma; AstraZeneca; Bayer; Blue Earth Diagnostics; Exelixis; Janssen; Lantheus Medical Imaging; Merck; Myovant Sciences; Myovant Sciences; Myriad Genetics; Novartis; Sanofi |
Research Funding - Astellas Scientific and Medical Affairs Inc; AstraZeneca; Bayer; Dendreon; Genentech; Myovant Sciences; Sanofi; Seattle Genetics/Astellas |
Travel, Accommodations, Expenses - Sanofi; Telix Pharmaceuticals |
|
|
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb/Celgene; Genentech; Janssen; Myovant Sciences; Novartis; Promontory |
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb/Celgene (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst); Novartis (Inst); Promontory Therapeutics (Inst) |
|
|
Consulting or Advisory Role - Johnson & Johnson/Janssen |
|
|
Leadership - Archimmune Therapeutics (I); Capio BioSciences (I) |
Stock and Other Ownership Interests - Archimmune Therapeutics (I); Capio Biosciences (I); Nanorobotics (I) |
Honoraria - Aptitude Health; Clinical Care Options; Curio Science; MJH Life Sciences; Peerview |
Consulting or Advisory Role - Aravive; AVEO; Bayer; Bristol-Myers Squibb; Calithera Biosciences; Dendreon; Eisai; Exelixis; Janssen; Lilly; Merck; Pfizer; QED Therapeutics; Sanofi/Aventis; Seagen |
Research Funding - Astellas Pharma; Janssen (Inst); Loxo/Lilly (Inst); Merck (Inst); Merrimack (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Tempus (Inst) |
Patents, Royalties, Other Intellectual Property - Circulating tumor cell novel capture by c-MET technology (Inst); Prochelators as Targeted Prodrugs for Prostate Cancer (Inst) |
Travel, Accommodations, Expenses - Janssen |
|
|
Employment - Janssen, A Johnson and Johnson Company |
Stock and Other Ownership Interests - Johnson and Johnson |
|
|
Employment - Janssen Research & Development |
Stock and Other Ownership Interests - Abbvie (I) |
|
|
|
Stock and Other Ownership Interests - Janssen |
|
|
Employment - Janssen Oncology |
Stock and Other Ownership Interests - Johnson and Johnson |
|
Angela Mennicke Lopez- Gitlitz |
Employment - Johnson & Johnson |
Stock and Other Ownership Interests - Johnson and Johnson |
Patents, Royalties, Other Intellectual Property - I am named as an inventor on the following patents: 1) WO 2021/224467 Treatment of Prostate Cancer with a Combination of Abiraterone Acetate and Niraparib 2) WO 2021/224469 Treatments of Prostate Cancer with Combinations of Abiraterone Acetate and Nirap |
|
|
No Relationships to Disclose |
|
|
Employment - Janssen; NY Presbyterian Hospital |
Stock and Other Ownership Interests - Johnson & Johnson/Janssen |
Research Funding - Alphina (I); Janssen; Kadmon (I) |
Travel, Accommodations, Expenses - Johnson & Johnson/Janssen |
|
|
Employment - Johnson & Johnson/Janssen |
Stock and Other Ownership Interests - Johnson & Johnson/Janssen |
|
|
Employment - Johnson & Johnson |
Stock and Other Ownership Interests - Johnson & Johnson/Janssen |
|
|
No Relationships to Disclose |
|
|
Research Funding - Amgen (Inst); Arvinas (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); crispr therapeutics (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); Gilead Sciences (Inst); Immunomedics (Inst); Janssen (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); ORIC Pharmaceuticals (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); Takeda (Inst) |
Travel, Accommodations, Expenses - Exelixis; Pfizer |